Table 1.
Clinicopathologic factors for patients undergoing breast conserving therapy
| Factor | Surgery First (n=2331) |
Neoadjuvant Chemotherapy (n=652) |
P value |
|---|---|---|---|
|
| |||
| Age | |||
| Median | 55 | 50 | < 0.001 |
| Range | 22 – 89 | 25 - 84 | |
|
| |||
| Histology | |||
| IDC | 2033 (87%) | 617 (95%) | <0.001 |
| ILC | 169 (7%) | 19 (3%) | |
| Mixed | 129 (6%) | 16 (2%) | |
|
| |||
| Clinical Stage | |||
| 0 | 31* (1%) | 0 (0%) | <0.001 |
| I | 1823 (78%) | 45 (7%) | |
| II | 459 (20%) | 451 (69%) | |
| III | 18 (1%) | 156 (24%) | |
|
| |||
| Nuclear grade | |||
| 1 | 266 (11%) | 16 (2%) | <0.001 |
| 2 | 1244 (53%) | 196 (30%) | |
| 3 | 785 (34%) | 431 (66%) | |
| Not reported | 36 (2%) | 9 (1%) | |
|
| |||
| ER | |||
| Positive | 1665 (71%) | 331 (51%) | <0.001 |
| Negative | 552 (24%) | 311 (48%) | |
| Unknown | 114 (5%) | 10 (1%) | |
|
| |||
| PR | |||
| Positive | 1364 (59%) | 292 (45%) | <0.001 |
| Negative | 802 (34%) | 347 (53%) | |
| Unknown | 165 (7%) | 13 (2%) | |
|
| |||
| HER2 | |||
| Positive | 122 (5%) | 114 (17%) | <0.001 |
| Negative | 1216 (52%) | 402 (62%) | |
| Unknown | 993 (43%) | 136 (21%) | |
|
| |||
| LVI | |||
| Present | 348 (15%) | 103 (16%) | 0.584 |
| Absent/Unknown | 1983 (85%) | 549 (84%) | |
|
| |||
| Multifocal disease | |||
| Yes | 155 (7%) | 64 (10%) | 0.006 |
| No | 2176 (93%) | 588 (90%) | |
|
| |||
| Margin Status | |||
| Negative | 2239 (96%) | 621 (95%) | 0.144 |
| Close (<2mm) | 63 (3%) | 26 (4%) | |
| Positive | 29 (1%) | 5 (1%) | |
|
| |||
| Pathologic Stage | |||
| 0 | 0 (0%) | 131 (20%) | <0.001 |
| I | 1540 (66%) | 217 (33%) | |
| II | 702 (30%) | 251 (38%) | |
| III | 89 (4%) | 53 (9%) | |
|
| |||
| Adjuvant | |||
| Chemotherapy | |||
| Yes | 980 (42%) | NA | NA |
| No | 1348 (58%) | ||
| Unknown | 4 (<1%) | ||
|
| |||
| Endocrine Therapy§ | |||
| Yes | 1293 (78%) | 294 (89%) | <0.001 |
| No | 372 (22%) | 37 (11%) | |
Abbreviations: IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; Mixed, invasive ductal and lobular carcinoma; ER, estrogen receptor; PR, progesterone receptor; HER2, HER2/neu; LVI, lymphovascular invasion
*
31 patients who underwent surgery first had a biopsy diagnosis of ductal carcinoma in situ but were found to have invasive disease on final pathologic evaluation.
§
Administration of endocrine therapy was determined only for patients with ER-positive disease